Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson Sells 8,330 Shares

Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson sold 8,330 shares of the firm’s stock in a transaction dated Wednesday, January 12th. The stock was sold at an average price of $46.52, for a total value of $387,511.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Norman Payson also recently made the following trade(s):

  • On Wednesday, January 5th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $46.99, for a total transaction of $391,426.70.
  • On Wednesday, December 22nd, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $50.62, for a total transaction of $421,664.60.
  • On Wednesday, December 15th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $47.60, for a total transaction of $396,508.00.
  • On Wednesday, December 8th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $50.65, for a total value of $421,914.50.
  • On Wednesday, December 1st, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $50.13, for a total value of $417,582.90.
  • On Tuesday, November 23rd, Norman Payson sold 8,130 shares of Progyny stock. The shares were sold at an average price of $54.26, for a total value of $441,133.80.
  • On Wednesday, November 17th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $63.36, for a total transaction of $527,788.80.
  • On Wednesday, November 10th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $63.18, for a total transaction of $526,289.40.
  • On Wednesday, November 3rd, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $61.40, for a total transaction of $511,462.00.
  • On Wednesday, October 27th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $60.69, for a total transaction of $505,547.70.

Shares of Progyny stock opened at $43.19 on Friday. The stock has a 50 day moving average of $51.97 and a 200 day moving average of $55.01. The firm has a market capitalization of $3.91 billion, a price-to-earnings ratio of 47.99 and a beta of 1.72. Progyny, Inc. has a fifty-two week low of $38.61 and a fifty-two week high of $68.32.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, November 4th. The company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $122.30 million for the quarter, compared to analysts’ expectations of $125.52 million. Progyny had a net margin of 18.96% and a return on equity of 29.67%. During the same quarter in the prior year, the company posted $0.05 earnings per share. Progyny’s revenue for the quarter was up 23.7% compared to the same quarter last year. Equities research analysts predict that Progyny, Inc. will post 0.54 earnings per share for the current fiscal year.

A number of research analysts have recently issued reports on the company. Citigroup lowered Progyny from a “buy” rating to a “neutral” rating and increased their target price for the company from $60.00 to $64.00 in a research report on Monday, November 22nd. Barclays boosted their target price on shares of Progyny from $72.00 to $80.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 28th. Berenberg Bank started coverage on shares of Progyny in a research note on Thursday, September 30th. They issued a “buy” rating and a $81.00 price target on the stock. Jefferies Financial Group assumed coverage on Progyny in a research note on Wednesday, December 1st. They set a “buy” rating and a $60.00 price objective for the company. Finally, Zacks Investment Research downgraded Progyny from a “hold” rating to a “sell” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $68.25.

A number of institutional investors have recently made changes to their positions in the stock. Captrust Financial Advisors lifted its holdings in Progyny by 19.1% during the 3rd quarter. Captrust Financial Advisors now owns 1,566 shares of the company’s stock worth $88,000 after buying an additional 251 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Progyny by 1.9% in the third quarter. Arizona State Retirement System now owns 14,468 shares of the company’s stock valued at $810,000 after acquiring an additional 270 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Progyny by 5.7% in the second quarter. PNC Financial Services Group Inc. now owns 5,177 shares of the company’s stock valued at $306,000 after acquiring an additional 278 shares in the last quarter. Louisiana State Employees Retirement System boosted its holdings in Progyny by 1.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 17,900 shares of the company’s stock valued at $901,000 after purchasing an additional 300 shares during the period. Finally, Quadrature Capital Ltd grew its stake in Progyny by 9.0% during the 3rd quarter. Quadrature Capital Ltd now owns 4,117 shares of the company’s stock worth $231,000 after purchasing an additional 340 shares in the last quarter. Institutional investors own 90.52% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Read More: Cash Flow

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.